As the nation struggles with prescription opioid abuse, misuse, and diversion, clinicians, the FDA, and pharmaceutical industry are under pressure to develop and prescribe medications with abuse-deterrent technologies that do not directly benefit patients, but target "unintended" uses. In the rush to "make everything abuse-deterrent," the chronic pain patient has been lost in the discussion. The long-term efficacy of opioid analgesics for chronic pain has also been hotly debated due to the lack of good long-term evidence in this patient population. However, the needs of the chronic pain patient are often lost in this debate. In addition, we will address other clinical needs of chronic pain patients, such as disturbed sleep and anxiety.
During this panel discussion, pain management and addiction specialists and a patient advocate will evaluate whether or not pain patients, needs are being prioritized in the opioid debate.
Martin D. Cheatle, PhD (moderator)
Director, Pain and Chemical Dependency Program,
Center for Studies of Addiction,
Perelman School of Medicine,
University of Pennsylvania,
Director, Behavioral Medicine,
Reading Health System,
West Reading, Pennsylvania
Jay Joshi, MD, DABA, DABAPM, FABAPM
Chief Executive Officer and Medical Director,
National Pain Centers,
Greater Chicago Area, Illinois
Chief Medical Officer, Wellness Center USA, Inc,
Chairman, Clinical Board of Directors,
National Pain Foundation
Heather Butler-Pierce, MEd
The Ehlers-Danlos National Foundation
Supported by an educational grant from
This activity is not certified for credit.